文献速递艾滋病与性传播感染

胰高血糖素样肽1受体激动剂促进HIV感染者体重下降

Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV.
PubMed 文献 · Clin Infect Dis · 2024-01-01

在加州大学圣地亚哥Owen诊所开展回顾性单中心队列研究,纳入2021年2月1日至2023年2月1日期间使用GLP-1RA的HIV感染者225例,平均治疗13个月。结果显示平均体重下降5.4 kg、BMI下降1.8 kg/m2、A1C下降0.6%。多变量分析中,较高基线BMI、治疗超过6个月及使用替尔泊肽与>5%体重下降显著相关。

要点

  • GLP-1RA治疗平均使HIV感染者体重下降5.4 kg、BMI下降1.8 kg/m2、A1C下降0.6%。
  • 治疗超过6个月与>5%体重下降相关(OR 3.12)。
  • 使用替尔泊肽与>5%体重下降相关(OR 5.46)。

核心结论

  • 使用GLP-1RA可使HIV感染者体重、BMI和A1C下降,为应对体重增加和糖尿病提供了额外策略。

研究设计与样本

  • 回顾性单中心队列研究,纳入2021年2月1日至2023年2月1日在加州大学圣地亚哥Owen诊所使用GLP-1RA的HIV感染者,要求至少3个月随访。
  • 共225例患者,平均接受13个月GLP-1RA治疗,其中85例(37.8%)达到GLP-1RA最大剂量。

主要发现

  • GLP-1RA治疗平均导致体重下降5.4 kg、BMI下降1.8 kg/m2、A1C下降0.6%。
  • 多变量分析中,较高基线BMI与>5%体重下降相关(OR 1.10,95%CI 1.03-1.16)。
  • GLP-1RA治疗持续时间>6个月与>5%体重下降相关(OR 3.12,95%CI 1.49-6.49)。
  • 使用替尔泊肽与>5%体重下降相关(OR 5.46,95%CI 1.44-20.76)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Weight gain and associated metabolic complications are increasingly prevalent among people with human immunodeficiency virus (PWH). Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are incretin-based therapies for diabetes and weight management that have been shown to result in substantial weight loss; however, studies of their effects in PWH are limited. METHODS: A retrospective single-center cohort study was conducted among PWH who were taking GLP-1RAs at the University of California, San Diego Owen Clinic between 1 February 2021 and 1 February 2023. Baseline clinical data were collected and changes in weight, body mass index (BMI), and hemoglobin A1C (A1C) before starting GLP-1RAs compared to the most recent clinic visit were calculated (with a minimum of 3 months follow-up time required). Logistic regression was performed to identify variables associated with >5% of total body weight loss. RESULTS: A total of 225 patients received on average 13 months of GLP-1RA therapy, with 85 (37.8%) achieving the maximum GLP-1RA dose. GLP-1RA therapy resulted, on average, in a weight loss of 5.4 kg, decrease in BMI by 1.8 kg/m2, and decrease in A1C by 0.6%. In the multivariable analysis, higher baseline BMI (odds ratio [OR], 1.10 [95% confidence interval {CI}, 1.03-1.16]), treatment duration of GLP-1RA therapy >6 months (OR, 3.12 [95% CI, 1.49-6.49]), and use of tirzepatide (OR, 5.46 [95% CI, 1.44-20.76]) were significantly more likely to be associated with >5% weight loss. CONCLUSIONS: Use of GLP-1RAs led to declines in weight, BMI, and A1C among PWH and offers an additional strategy to address weight gain and diabetes.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Nguyen Q, Wooten D, Lee D, et al. Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV. Clin Infect Dis. 2024. PMID: 38501237. doi:10.1093/cid/ciae151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。